

## Change to *C. difficile* Testing Algorithm

Date: January 3rd, 2022

---

Effective Date: January 5<sup>th</sup>, 2022

Our current testing algorithm for laboratory diagnosis of *C. difficile* disease utilizes an Enzyme Immunoassay (EIA) for detection of Toxin and GDH (a non-specific marker for *C. difficile*) followed by PCR assay for detection of Toxin gene if Tox-GDH+ by EIA. This testing approach is geared toward providing maximum sensitivity for detection of Toxin or Toxin gene while accepting reduced specificity. More recent experience and data indicate, however, that the reduced specificity of the current testing approach can detect colonization with *C. difficile* in the absence of toxin production and lead to over diagnosis of disease and unnecessary treatment. After discussions with Infection Prevention, Infection Diseases, medical leadership of URM and its affiliates, and representation from residential facilities, we will implement a new testing approach which will first test for Toxin gene by PCR followed by EIA for Toxin if the PCR assay is positive. This new testing approach will be implemented January 5, 2022. Ordering in EPIC (inpatient and outpatients) and affiliate computer systems has been adjusted to reflect this new testing approach. Example test results with interpretation are shown below.

- C. difficile PCR:** Positive  
**C. difficile Toxin:** Positive  
**Interpretation:** Suggests *C. difficile* disease. Test results should be interpreted in clinical context.
- C. difficile PCR:** Positive  
**C. difficile Toxin:** Negative  
**Interpretation:** Suggests *C. difficile* colonization; occasional patients with *C. difficile* disease may have negative toxin. Test results should be interpreted in clinical context.
- C. difficile PCR:** Negative  
**C. difficile Toxin:** Not Done  
**Interpretation:** Negative. PCR has a negative predictive value of >99%.

For questions or additional information contact Dwight J. Hardy, Ph.D. (see below contact information).

From: Dwight J. Hardy, Ph.D.  
Director, Clinical Microbiology  
UR Medicine Labs  
University of Rochester Medical Center  
Phone: 585-275-1408  
Email: [dwight\\_hardy@urmc.rochester.edu](mailto:dwight_hardy@urmc.rochester.edu)